Project Twenty21

Drug Science launched Europe’s first and biggest national medical cannabis registry, called Project Twenty21, on the 7th November 2019. Project TWENTY21 will enrol 20,000 patients by the end of 2021, creating the largest body of evidence for the effectiveness and tolerability of medical cannabis – with an aim to demonstrate to policymakers that medical cannabis  …


Statement on the dangers posed by e-cigarettes

Drug Science stands by its e-cigarette analysis from 2014, any way of radically reducing the death toll from tobacco would be a worldwide public health triumph. e-cigarettes are not the solution to end the ever-increasing death toll caused by tobacco. However, they have proven to be an incredibly effective tool for tens of thousands of  …


Press Release: Government decision on cannabis-related medicinal products draws criticism from independent scientific body, Drug Science.

Today (13th August 2019), the independent scientific body Drug Science has responded with disappointment to a decision by the National Institute for Health and Care Excellence (NICE), relating to cannabis-related medical products. In November 2018, the then Home Secretary Sajid Javid introduced regulations so that cannabis-derived medicinal products would be available on prescription. This change  …


First safety study of MDMA-assisted psychotherapy in patients with alcohol use disorder

Read the full paper here (open access) We present the preliminary data in the Bristol-Imperial MDMA-for-Alcoholism (BIMA) study, an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder (AUD). At this stage, eleven participants have completed the full 8-week MDMA-assisted  …